8-K current report · filed Nov 2, 2026

Krystal Biotech, Inc. (KRYS) 8-K Current Report: November 2, 2026

Item 2.02Item EX-99.1KRYS overview

Short answer

Krystal Biotech, Inc. (KRYS) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results announced for quarter ended September 30, 2026.

Krystal Biotech, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results announced for quarter ended September 30, 2026
  • Detailed financial results and management commentary in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • 3Q revenue $127.3M, up 30% YoY, with 94% gross margin, reinforcing VYJUVEK’s commercial momentum
  • 3Q net income $63.1M, down from $79.4M as income tax expense rose to $17.1M
  • Cash and investments $1.2B, supporting pipeline expansion and global commercialization without apparent near-term funding pressure
  • Board authorized $400M share repurchase program over the next two years, potentially supporting per-share value while reducing financial flexibility
  • KB113 showed regression in over 80% of assessed BCC lesions in a three-patient Gorlin syndrome study, an early but clinically limited proof-of-concept signal

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Krystal Biotech, Inc. 8-K filings

Get the next KRYS 8-K as it lands

Follow KRYS for push alerts, or ask the research agent what this filing means.